

07-16-01

A

07/13/01

JCS91 U.S. PRO



Docket Number LA 24B Cont 1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 600712206US  
Express Mail Label NumberJuly 13, 2001  
Date of depositJCS91 U.S. PRO  
09/905235

10/13/01

Address to: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

## UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **continuation** of prior Application No. 09/390,275, filed September 7, 1999.

Applicant (or identifier): ROBL ET AL.

Title: METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN AP2 INHIBITOR AND COMBINATION

Enclosed are:

1. ☒ Specification (Including Claims and Abstract) - 59 pages
  2. ☒ Drawings - 1 sheet of Formal Drawings.
  3. Declaration and Power of Attorney
    - a. ☐ Newly executed (original or copy)
    - b. ☒ Copy from a prior application (signed or with indication that original was signed)
      - i. ☐ Deletion of Inventors  
Signed statement attached deleting inventor(s) named in the prior application
  4. ☒ Incorporation By Reference  
The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
  5. ☐ Microfiche Computer Program (appendix)
  6. Nucleotide and/or Amino Acid Sequence Submission
    - ☒ Computer Readable Copy
    - ☒ Paper Copy
    - ☒ Statement Verifying Identity of Above Copies
  7. ☒ Preliminary Amendment
  8. ☒ Assignment Papers (Cover Sheet & Document(s)) ✓
  9. ☐ English Translation of
  10. ☐ Information Disclosure Statement
  11. ☐ Certified Copy of Priority Document(s)
  12. ☒ Return Receipt Postcard
  13. ☐ Other:
- ☒ The right to elect an invention or species that is different from that elected in parent Application No. 09/390,275 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.

09905235 . 071301

Filing fee calculation:

- ☒ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.  
☐ Before calculating the filing fee, please cancel claims

Basic Filing Fee						\$	710
Multiple Dependent Claim Fee (\$ 270)						\$	
Foreign Language Surcharge (\$ 130)						\$	
	For	Number Filed		Number Extra		Rate	
Extra Claims	Total Claims	20	-20	0	x	\$ 18	= \$
	Independent Claims	2	-3	0	x	\$ 80	= \$
TOTAL FILING FEE						\$	710

- ☒ Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$710. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.


Please address all correspondence to the address associated with Customer No. 23914, which is currently:

Maria J. Mathias  
Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (609) 252-4526.

Respectfully submitted,

Date:

  
Ronald S. Hermenau  
Attorney for Applicants  
Reg. No. 34,620  
Tel. No. (609) 252-5781

09905235-071301

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ronald A. Hermeneau  
Type or print name

  
Signature

7/13/01  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: NOT ASSIGNED YET

FILED: HEREWITH

FOR: METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN  
AP2 INHIBITOR AND COMBINATION

Assistant Commissioner for Patents  
Washington, D.C. 20231


SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same. This submission includes no new matter. Applicants are submitting this sequence listing based on the prosecution of co-pending application Serial No., 09/391,053.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5781  
Date: 7/13/01

  
Ronald S. Hermeneau  
Attorney for Applicants  
Reg. No. 34,620

099052235.071301